Ophthalmics Collaboration and Licensing Deals 2019-2025
상품코드:1854035
리서치사:Current Partnering
발행일:2025년 10월
페이지 정보:영문 200+ Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 바이오의약품 산업에 대해 조사 분석했으며, 2019년부터 2025년까지의 안과 분야 344건의 공동 연구 및 라이선싱 계약에 대한 상세한 데이터와 계약 조건에 대한 정보를 전해드립니다.
목차
주요 요약
제1장 소개
제2장 안과 계약 동향
소개
과거 몇 년간 안과 제휴
안과 제휴 : 계약 유형별
안과 제휴 : 산업 부문별
안과 제휴 : 개발 단계별
안과 제휴 : 기술 유형별
안과 제휴 : 적응증별
제3장 안과 제휴에 대한 재무적 계약 조건
소개
안과 제휴에 관한 공개된 재무 조건
안과 제휴 헤드라인 금액
안과 계약 선급금
안과 계약 단계별 기술료
안과 로열티율
제4장 주요 안과 계약과 계약 기업
소개
안과 제휴에서 가장 활발
안과에서 가장 활발한 계약 기업 리스트
금액으로 상위 안과 계약
제5장 안과 계약 문서 디렉토리
소개
계약서가 이용 가능한 안과 제휴 계약
제6장 안과 계약 : 치료 표적별
소개
계약 : 안과 치료 표적별
계약 디렉토리
계약 디렉토리 - 안과 계약 : 기업별(A-Z, 2019-2025년)
계약 디렉토리 - 안과 계약 : 기술 유형별(2019-2025년)
계약 유형의 정의
Biopharma Research Ltd 소개
Current Partnering
Current Agreements
Current Partnering의 최근 보고서 타이틀
KSM
영문 목차
영문목차
Ophthalmics Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the ophthalmics deals entered into by the worlds leading biopharma companies.
Fully revised and updated, the report provides details of 344 ophthalmics deals from 2019 to 2025.
The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration and licensing deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of ophthalmics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in ophthalmics dealmaking.
Chapter 3 covers the financial deal terms for deals signed in the ophthalmics field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.
Chapter 4 provides a review of the top 25 most active biopharma companies in ophthalmics dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive and detailed review of ophthalmics deals signed and announced since 2019 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of ophthalmics deals listed by theraeutic target.
The report also includes numerous table and figures that illustrate the trends and activities in ophthalmics deal making since 2019.
In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Key benefits
Ophthalmics Collaboration and Licensing Deals provides the reader with the following key benefits:
Understand deal trends since 2019
Browse ophthalmics collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, therapy focus and technology type
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time
Report scope
Ophthalmics Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of ophthalmics trends and structure of deals entered into by leading biopharma companies worldwide.
Ophthalmics Collaboration and Licensing Deals includes:
Trends in ophthalmics dealmaking in the biopharma industry
Overview of collaboration and licensing deal structure
Directory of ophthalmics deal records covering pharmaceutical and biotechnology
The leading ophthalmics deals by value
Most active ophthalmics licensing dealmakers
In Ophthalmics Collaboration and Licensing Deals, the available deals are listed by:
Company A-Z
Headline value
Therapeutic area
Technology type
Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
Ophthalmics Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Table of Contents
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in ophthalmics dealmaking
2.1. Introduction
2.2. Ophthalmics partnering over the years
2.3. Ophthalmics partnering by deal type
2.4. Ophthalmics partnering by industry sector
2.5. Ophthalmics partnering by stage of development
2.6. Ophthalmics partnering by technology type
2.7. Ophthalmics partnering by therapeutic indication
Chapter 3 - Financial deal terms for ophthalmics partnering
3.1. Introduction
3.2. Disclosed financials terms for ophthalmics partnering
3.3. Ophthalmics partnering headline values
3.4. Ophthalmics deal upfront payments
3.5. Ophthalmics deal milestone payments
3.6. Ophthalmics royalty rates
Chapter 4 - Leading ophthalmics deals and dealmakers
4.1. Introduction
4.2. Most active in ophthalmics partnering
4.3. List of most active dealmakers in ophthalmics
